Vaxart's Founder and Chief Scientific Officer Provides Video Update to Stockholders
Dr. Sean Tucker, Founder and CSO of Vaxart, Urges Stockholders to Vote FOR Reverse Stock Split Proposal by 11:59 p.m. Eastern Time on June 1, 2025
Company Corrects Record on Common Misconceptions Regarding the Reverse Stock Split Proposal
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the 'Company' OR 'Vaxart') today announces a video update for stockholders by Dr. Sean Tucker. The video is available on Vaxart's investor relations website at investors.vaxart.com. In the video, Dr. Tucker urges stockholders to vote FOR Proposal No. 2, which grants the Board of Directors authority to implement a reverse split that would enable Vaxart regain compliance with Nasdaq's minimum bid price rule.
Additionally, to ensure stockholders have accurate information as they consider this important proposal, the Company addresses several misconceptions in the attached fact sheet:
A PDF accompanying this announcement is available at http://ml.globenewswire.com/Resource/Download/d6b3e0b1-6bf0-4a26-a846-0bc63d03b8dd
Vaxart encourages all stockholders of record on March 26, 2025 who have not yet voted to do so by 11:59 p.m. Eastern Time on June 1, 2025. The Company also reminds those who have previously voted against Proposal No. 2 that they can change their vote in favor of the proposal.
If you have any questions or need assistance with voting, please contact Vaxart's proxy solicitation firm:
Campaign Management, LLC
Toll-Free: 1-855-264-1527
Email: info@campaign-mgmt.com
About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart's development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the 'Securities Act') and Section 21E of the Securities Exchange Act of 1934, as amended (the 'Exchange Act'), which are subject to the 'safe harbor' created by those sections, concerning our business, operations, and financial performance and condition as well as our plans, objectives, and expectations for business operations, funding, financial performance and condition, and regaining compliance with the Nasdaq minimum bid price requirement. Any statements contained herein that are not of historical facts may be deemed to be forward-looking statements. You can identify these statements by words such as 'anticipate,' 'assume,' 'believe,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'should,' 'will,' 'would,' and other similar expressions that are predictions of or indicate future events and future trends. These forward-looking statements are based on current expectations, estimates, forecasts, and projections about our business and the industry in which we operate and management's beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties, and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this press release may turn out to be inaccurate. Factors that could materially affect our business operations and financial performance and condition include, but are not limited to, those risks and uncertainties described under 'Item 1A - Risk Factors' in our Annual Report on Form 10-K for the year ended December 31, 2024 and any risk factors disclosed in any subsequent Quarterly Reports on Form 10-Q. You are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are based on information available to us as of the date of this press release. Unless required by law, we do not intend to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise. You should, however, review the factors and risks we describe in the reports we will file from time to time with the SEC after the date of this press release.
Participants in the Solicitation
The Company and its directors, executive officers, and certain employees and other persons may be deemed to be participants in the solicitation of proxies from the Company's stockholders in connection with the business to be conducted at the annual meeting of stockholders. Investors and security holders may obtain more detailed information regarding the names, affiliations, and interests of the Company's directors and executive officers in the definitive proxy statement filed in connection with the annual meeting of stockholders as well as the Company's other filings with the U.S. Securities and Exchange Commission (the 'SEC'), all of which may be obtained free of charge at the website maintained by the SEC at www.sec.gov.
This press release was published by a CLEAR® Verified individual.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Trump sends Powell a list of global interest rates, says Fed should lower rate to 1%
President Donald Trump on Monday continued hammering at the U.S. Federal Reserve to ease monetary policy, sending Fed Chair Jerome Powell a list of central bank interest rates around the world adorned with handwritten commentary saying the U.S. rate should be between Japan's 0.5 per cent and Denmark's 1.75 per cent, and telling him he was 'as usual, 'too late.'' 'You should lower the rate by a lot. Hundreds of billions being lost,' Trump said in the note, which was also posted to social media with further commentary from the President saying that being a central banker in the U.S. was 'one of the easiest, yet most prestigious jobs in America, and they have should be paying 1% interest, or better!' A 1 per cent policy rate in the past in the U.S. has been associated with weak, even recessionary economic growth rates and periods of low inflation. As have many of Trump's posts on monetary policy, this one seemed to conflate the benchmark short-term interest rate set by the Fed with the interest rate investors demand to hold U.S. and other debt, which can be influenced by Fed policy but is also connected to views about the U.S. economy, inflation, geopolitics and institutional stability. With the unemployment rate low and inflation above their 2 per cent target, Fed officials have been reluctant to cut interest rates from the current 4.25 per cent to 4.5 per cent range until it is clear that the Trump administration's tariff plans won't lead to a fresh surge in prices. Federal Reserve officials continued to raise those concerns on Monday, while Treasury Secretary Scott Bessent began mapping out the likely plan for naming Powell's replacement for when he leaves the job next May. Trump cannot fire Powell over a policy dispute, but last week urged him to resign. Tariff threats put the Federal Reserve in 'uncomfortable purgatory' Bessent in recent days, by contrast, has pointed to a more conventional handover of power at the Fed instead of attempts to influence monetary policy through early appointment of a 'shadow chair' or other methods. 'There's a seat opening up ... in January. So we've given thought to the idea that perhaps that person would go on to become the chair when Jay Powell leaves in May,' Bessent said on Bloomberg TV. Current Governor Adriana Kugler's term expires in January. Bessent on Friday said a January opening would 'probably mean an October, November nomination' with Senate confirmation following. One person under consideration as chair, Governor Christopher Waller, is already on the board and participating in monetary policy discussions; others, like former governor Kevin Warsh, would remain on the sidelines until a seat comes open and the nominee for it is confirmed by the Senate. Though Trump's insistence on rate cuts could make for a difficult confirmation hearing – the Fed is supposed to act independently of the wants of elected officials – data this summer will be key to whether tensions between the White House and the central bank intensify or ease in coming weeks if policy makers find a path to rate cuts on their own. Investors expect the Fed to resume cutting the benchmark policy rate at the September meeting and move steadily lower from there. Economists from Goldman Sachs, who have been pessimistic about the U.S. growth and inflation outlook and had expected the Fed to wait until the end of the year to cut rates, on Monday pulled their estimated first cut into September as well. 'We thought that the peak summer tariff effects on monthly inflation would make it awkward to cut sooner. But the very early evidence suggests that the tariff effects look a bit smaller than we expected, other disinflationary forces have been stronger, and we suspect that the Fed leadership shares our view that tariffs will only have a one-time price level effect,' Goldman economists wrote. Waller has said cuts could be warranted as soon as the Fed's July meeting, and paused if inflation does begin to rise. The Fed receives new jobs data on Thursday, covering the month of June, which will indicate if the labour market is beginning to sputter, a development that could also add to the case for rate cuts sooner rather than later. New inflation data is released next week. July 9 is also top of mind for the Fed: That's the day the current suspension of some of Trump's tariffs expires, and it remains unclear whether import taxes will skyrocket or Trump's program be delayed again pending negotiations. Federal Reserve Bank of Atlanta President Raphael Bostic repeated on Monday that he still sees the central bank cutting its interest rate target just once this year, while suggesting there's no urgency to act given the level of uncertainty. 'I think we actually have some luxury to be patient because labour markets are actually quite solid,' Bostic said in an event hosted by Market News International. 'I think there is actually more pricing to come, and it is more a question of time, of when and not if ... This is still going to take some time before we'll sort of know the answer to those sorts of things.'
CTV News
2 hours ago
- CTV News
Over 14 million people could die from U.S. foreign aid cuts: study
Demonstrators and lawmakers rally against U.S. President Donald Trump and his ally Elon Musk as they disrupt the federal government, including dismantling the U.S. Agency for International Development, which administers foreign aid approved by Congress, on Capitol Hill in Washington, Wednesday, Feb. 5, 2025. (AP Photo/J. Scott Applewhite) PARIS, France — More than 14 million of the world's most vulnerable people, a third of them small children, could die because of the Trump administration's dismantling of U.S. foreign aid, research projected on Tuesday. The study in the prestigious Lancet journal was published as world and business leaders gather for a UN conference in Spain this week hoping to bolster the reeling aid sector. The U.S. Agency for International Development (USAID) had provided over 40 percent of global humanitarian funding until Donald Trump returned to the White House in January. Two weeks later, Trump's then-close advisor -- and world's richest man -- Elon Musk boasted of having put the agency 'through the woodchipper'. The funding cuts 'risk abruptly halting -- and even reversing -- two decades of progress in health among vulnerable populations,' warned study co-author Davide Rasella, a researcher at the Barcelona Institute for Global Health (ISGlobal). 'For many low- and middle-income countries, the resulting shock would be comparable in scale to a global pandemic or a major armed conflict,' he said in a statement. Looking back over data from 133 nations, the international team of researchers estimated that USAID funding had prevented 91 million deaths in developing countries between 2001 and 2021. They also used modelling to project how funding being slashed by 83 percent -- the figure announced by the U.S. government earlier this year -- could affect death rates. The cuts could lead to more than 14 million avoidable deaths by 2030, the projections found. That number included over 4.5 million children under the age of five -- or around 700,000 child deaths a year. For comparison, around 10 million soldiers are estimated to have been killed during World War I. Programmes supported by USAID were linked to a 15-percent decrease in deaths from all causes, the researchers found. For children under five, the drop in deaths was twice as steep at 32 percent. USAID funding was found to be particularly effective at staving off preventable deaths from disease. There were 65 percent fewer deaths from HIV/AIDS in countries receiving a high level of support compared to those with little or no USAID funding, the study found. Deaths from malaria and neglected tropical diseases were similarly cut in half. 'Time to scale up' After USAID was gutted, several other major donors including Germany, the UK and France followed suit in announcing plans to slash their foreign aid budgets. These aid reductions, particularly in the European Union, could lead to 'even more additional deaths in the coming years,' study co-author Caterina Monti of ISGlobal said. But the grim projections for deaths were based on the current amount of pledged aid, so could rapidly come down if the situation changes, the researchers emphasised. Dozens of world leaders are meeting in the Spanish city of Seville this week for the biggest aid conference in a decade. The U.S., however, will not attend. 'Now is the time to scale up, not scale back,' Rasella said. Before its funding was slashed, USAID represented 0.3 percent of all U.S. federal spending. 'U.S. citizens contribute about 17 cents per day to USAID, around $64 per year,' said study co-author James Macinko of the University of California, Los Angeles. 'I think most people would support continued USAID funding if they knew just how effective such a small contribution can be to saving millions of lives.'
Globe and Mail
2 hours ago
- Globe and Mail
Oracle (ORCL) Stock Hits an All-Time High Amid Increased Cloud Demand
Optimism surrounding Oracle's ORCL cloud and AI infrastructure endeavors pushed its stock to an all-time high of $228 a share on Monday. This comes as the enterprise cloud leader has secured lucrative contracts thanks to its momentum in AI, with many analysts starting to raise their price targets for Oracle stock. That said, let's see if now is a good time to buy ORCL for higher highs. Massive Cloud Deal & AI Momentum Although the identity of the customer was not disclosed, Oracle stock spiked +4% on Monday following news of a regulatory filing in which the company had signed a massive $30 billion annual cloud services deal. Given the scale and nature of the contract, many analysts believe the client could be a major AI player like OpenAI. To that point, Oracle and OpenAI have formed a strategic partnership, collaborating on a massive AI training hub in Texas. As part of a broader $500 billion AI infrastructure initiative, which also includes Nvidia NVDA, Oracle is the venture's core infrastructure provider. Deemed Project Stargate, Oracle will be helping to expand OpenAI's compute capacity beyond Microsoft MSFT Azure. Embarking on a multi-cloud strategy, Microsoft and OpenAI are using Oracle Cloud Infrastructure (OCI) to integrate Azure's AI cloud platform to produce enhanced training for large-language models (LLMs). With demand booming for OCI, Oracle's MultiCloud revenue is reportedly growing at over 100% in correlation with the need to support generative AI workloads such as OpenAI's ChatGPT. Reporting its fiscal fourth-quarter results earlier in the month, Oracle's Q4 sales stretched 11% year over year to $15.9 billion, pinpointing that its MultiCloud database revenue spiked 115% sequentially, driven by partnerships with Amazon's AMZN AWS and Alphabet's GOOGL Google Cloud, along with Microsoft Azure. ORCL Performance & Valuation Comparison Following today's rally, ORCL is up +30% in 2025. More impressive, Oracle stock is now sitting on +200% gains in the last three years to vastly outperform the broader indexes and its Zacks Computer-Software Market's +95%, which includes Microsoft stock at +90%. Image Source: Zacks Investment Research Furthermore, despite Oracle's blazing stock performance, at 31.3X forward earnings, ORCL still trades beneath Microsoft's 37.1X and their Zacks Computer-Software Industry average of 35.9X. Analysts Upgrade ORCL Price Target to $250 Citing strong cloud momentum, AI infrastructure growth, and a bullish outlook for Oracle's current fiscal year 2026, several financial firms have upped their price target for ORCL shares to $250, including analysts at Stifel, UBS, and Guggenheim. Bottom Line At the moment, Oracle stock currently lands a Zacks Rank #3 (Hold). However, it wouldn't be surprising if a buy rating is on the way and perhaps higher highs for ORCL, as earnings estimates for Oracle are likely to rise in correlation with the announcement of its lucrative cloud services deal. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Oracle Corporation (ORCL): Free Stock Analysis Report Inc. (AMZN): Free Stock Analysis Report Microsoft Corporation (MSFT): Free Stock Analysis Report NVIDIA Corporation (NVDA): Free Stock Analysis Report Alphabet Inc. (GOOGL): Free Stock Analysis Report
